FDA Accepts Astellas/Seagen’s Submissions for Padcev’s Full Approval, Label Expansion

The US FDA has accepted two applications filed by Astellas Pharma and partner Seagen for full approval of their antibody-drug conjugate (ADC) Padcev (enfortumab vedotin) and its label expansion. The target action data was set for August 17, with priority...read more